Axsome Therapeutics Inc

Axsome Therapeutics Inc

AXSM

Market Cap$5.18B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Axsome Therapeutics IncAxsome Therapeutics Inc-18.5--523%13.53.9
$179.33

Target Price by Analysts

65.8% upsideAxsome Therapeutics Target Price DetailsTarget Price
$20.54

Current Fair Value

81% downside

Overvalued by 81% based on the discounted cash flow analysis.

Share Statistics

Market cap$5.18 Billion
Enterprise Value$5.09 Billion
Dividend Yield$0 (0%)
Earnings per Share$-5.99
Beta0.45
Outstanding Shares48,871,163

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-18.47
PEG141.15
Price to Sales13.52
Price to Book Ratio108.14
Enterprise Value to Revenue11.77
Enterprise Value to EBIT-18.63
Enterprise Value to Net Income-19
Total Debt to Enterprise0.04
Debt to Equity3.94

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Axsome Therapeutics Inc

CEO: Herriot Tabuteau

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...